Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance

Rhea-AI Summary

Tandem Diabetes Care (Nasdaq: TNDM) released its Q2 2024 financial results and raised its full-year 2024 sales guidance. Key highlights include:

Sales: Worldwide GAAP sales increased by 13% to $221.9M, while non-GAAP sales rose 12% to $221.8M compared to Q2 2023. US shipments of insulin pumps surged 33% sequentially. However, international shipments fell by 6%.

New Products: The company launched the Tandem Mobi integrated with the Dexcom G7 CGM in the US and began the international rollout of Tandem Source. Additionally, enrollment for the Control-IQ pivotal study for type 2 diabetes was completed.

Financials: GAAP gross profit increased to $112.8M from $101.7M. However, the GAAP operating loss was $30.8M, and the GAAP net loss was $30.8M. Non-GAAP operating loss stood at $30.9M, and non-GAAP net loss was $30.9M.

Guidance: The company increased its full-year 2024 sales guidance, reflecting strong demand for its latest technologies.

Positive

• Worldwide GAAP sales increased by 13% to $221.9M.
• US insulin pump shipments rose 33% sequentially.
• Launched Tandem Mobi with Dexcom G7 CGM integration in the US.
• Completed enrollment for Control-IQ pivotal study for type 2 diabetes.
• Increased full-year 2024 sales guidance.

Negative

• International insulin pump shipments decreased by 6%.
• GAAP operating loss was $30.8M.
• GAAP net loss was $30.8M.
• Non-GAAP operating loss was $30.9M.
• Non-GAAP net loss was $30.9M.
• Adjusted EBITDA was negative $1.9M.

Insights

Financial Analyst

Tandem Diabetes Care's Q2 2024 results show promising growth, with worldwide GAAP sales increasing 13% to $221.9 million. The company's non-GAAP sales also grew by 12% to $221.8 million. This outperformance, driven by strong demand for new technologies like Tandem Mobi, has led to an increase in full-year 2024 sales guidance.

Key highlights include:

• Over 20,000 pumps shipped in the U.S., a 33% sequential increase from Q1 2024
• Successful launch of Tandem Mobi with Dexcom G7 CGM integration in the U.S.
• Completed enrollment for Control-IQ pivotal study for type 2 diabetes
• International expansion with Tandem Source launch

While sales growth is impressive, the company still reported a GAAP operating loss of $30.8 million (-14% of sales), an improvement from $38.8 million (-20% of sales) in Q2 2023. The non-GAAP operating loss widened to $30.9 million (-14% of sales) from $22.4 million (-11% of sales) last year.

The company's gross margin remained relatively stable at 51% (both GAAP and non-GAAP), indicating consistent production efficiency despite growth. However, the widening non-GAAP operating loss suggests increased spending on R&D and marketing to support new product launches and market expansion.

Tandem's strategy of offering customer choice through programs like Tandem Choice appears to be paying off, contributing to market expansion. The company's focus on technological innovation and international growth could drive long-term value, but investors should monitor the path to profitability closely.

Medical Device Expert

Tandem Diabetes Care's Q2 2024 results highlight significant advancements in diabetes management technology. The launch of Tandem Mobi with Dexcom G7 CGM integration represents a major leap forward in insulin delivery systems. This integration allows for more precise glucose monitoring and insulin dosing, potentially improving patient outcomes and quality of life.

The completion of enrollment for the Control-IQ pivotal study for type 2 diabetes is another important development. If successful, this could dramatically expand Tandem's addressable market, as type 2 diabetes affects a much larger population than type 1. The potential approval of Control-IQ for type 2 diabetes could be a game-changer for the company and the diabetes care industry as a whole.

The 33% sequential increase in U.S. pump shipments indicates strong market acceptance of Tandem's products. This growth, coupled with the international expansion through Tandem Source, suggests that the company is successfully executing its global growth strategy.

However, it's important to note that while Tandem is making strides in technology and market expansion, the company is still operating at a loss. The transition from innovation to profitability will be a key challenge for Tandem in the coming years. Investors should keep a close eye on how effectively the company can leverage its technological advancements to improve its financial performance.

Overall, Tandem's focus on innovation and expanding its product portfolio positions it well in the competitive diabetes care market, but the path to sustained profitability remains a critical factor to monitor.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2024 and increased sales guidance for the year ending December 31, 2024.

Second Quarter 2024 Highlights

• Worldwide GAAP sales increased 13 percent to $221.9 million compared to second quarter 2023; worldwide non-GAAP sales⁽¹⁾ increased 12 percent to $221.8 million compared to second quarter 2023.
• More than 20,000 pumps shipped in the United States, a sequential increase of 33 percent compared to first quarter 2024.
• Launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM) sensor integration in the United States.
• Completed enrollment for Control-IQ pivotal study to support an expanded indication for Control-IQ to people living with type 2 diabetes.
• Began the launch of Tandem Source outside the United States.

“Our financial outperformance in the second quarter was bolstered by strong demand for our latest technology offerings, namely Tandem Mobi, which drove our expansion of the insulin pump market,” said John Sheridan, president and chief executive officer. “The early enthusiasm for our expanding portfolio supports our strategy to offer our customers choice as we work to bring the benefits of our technology to more people living with diabetes worldwide.”

Second Quarter 2024 Sales Results Compared to 2023

From September 2022 through February 2024, the Company offered the Tandem Choice Program (Tandem Choice) to eligible t:slim X2 customers to provide a pathway to ownership of Tandem Mobi, for a fee when available. At the end of the second quarter, the Company began offering eligible t:slim X2 owners the opportunity to switch to a Tandem Mobi under the terms of the program. As a result of this program, the Company is providing select financial results for both GAAP and non-GAAP. Additional information, including the accounting treatment of this program and other non-GAAP measures, can be found under Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release. See also “Non-GAAP Financial Measures” below.

	Three Months Ended														Six Months Ended
	June 30,														June 30,
	2024							2023							2024							2023
($ in millions)	GAAP			Non-GAAP(1)				GAAP			Non-GAAP(1)				GAAP			Non-GAAP(1)				GAAP			Non-GAAP(1)
United States	$	156.7		$	156.6			$	142.5		$	144.8			$	286.5		$	287.5			$	273.7		$	278.1
Outside United States		65.2			65.2				53.4			53.4				127.1			127.1				91.6			91.6
Total Worldwide	$	221.9		$	221.8			$	195.9		$	198.2			$	413.6		$	414.6			$	365.3		$	369.7

Second Quarter 2024 Additional Results Compared to Second Quarter 2023

• Sales: In the United States, GAAP sales included $0.2 million incremental sales relating to Tandem Choice compared to a sales deferral of $2.3 million. Non-GAAP sales do not include Tandem Choice-related sales deferrals or recognition.
  
  Worldwide shipments increased 3 percent driven by an 8 percent increase in the United States. Domestic shipments were more than 20,000 pumps. Shipments outside the United States decreased 6 percent to nearly 10,000 pumps.
  
  
• Gross profit: GAAP gross profit was $112.8 million, compared to $101.7 million. GAAP gross margin was 51 percent compared to 52 percent.
  
  Non-GAAP gross profit⁽¹⁾ was $112.7 million compared to $104.0 million. Non-GAAP gross margin⁽¹⁾ was 51 percent compared to 52 percent.
  
  
• Operating loss: GAAP operating loss was $30.8 million, or negative 14 percent of sales, compared to $38.8 million, or negative 20 percent of sales.
  
  Non-GAAP operating loss⁽¹⁾ was $30.9 million, or negative 14 percent of sales, compared to $22.4 million or negative 11 percent of sales.
  

• Net loss: GAAP net loss was $30.8 million, compared to $35.8 million.
  
  Non-GAAP net loss⁽¹⁾ was $30.9 million compared to $19.4 million.
  
  Adjusted EBITDA⁽¹⁾ was negative $1.9 million, or negative 1 percent of sales, compared to $5.3 million, or 3 percent of sales.

(1) A reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures and additional information can be found in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release. Also see “Non-GAAP Financial Measures” below for additional information.

See tables for additional financial information.

2024 Financial Guidance

The Company’s non-GAAP guidance for the fiscal year ending December 31, 2024 is set forth below. The most directly comparable GAAP financial measures are not accessible on a forward-looking basis due to the high degree of complexity in the accounting treatment for the Tandem Choice program. For a description of non-GAAP sales, non-GAAP gross margin, and Adjusted EBITDA margin, as well as an illustration of the reconciliation from the most directly comparable GAAP financial measures, refer to Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release. Also see “Non-GAAP Financial Measures” below for additional information.

“We increased our worldwide sales expectations to 15 percent annual growth, which reflects the strong performance of our recent product launches and consistently high retention rates for our existing customer base,” said Leigh Vosseller, executive vice president and chief financial officer. “Driving growth is a top priority for our business, as we balance the associated investments with opportunities to drive leverage in pursuit of our long-term profitability objectives.”

For the year ending December 31, 2024, the Company is updating its 2024 financial guidance as follows:

• Non-GAAP sales are estimated to be approximately $885 million to $892 million for the full year and $222 million to $225 million in the third quarter.
  • Sales in the United States of $640 million to $645 million for the full year and $162 million to $165 million in the third quarter.
  • Sales outside the United States of approximately $245 million to $247 million for the full year and $60 million in the third quarter.
• Non-GAAP gross margin is estimated to be approximately 51 percent for the full year and the third quarter.
• Adjusted EBITDA margin is estimated to be breakeven as a percent of sales for the full year and the third quarter.
• Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $120 million. This includes:
  • Approximately $100 million non-cash, stock-based compensation expense.
  • Approximately $20 million depreciation and amortization expense.

Non-GAAP Financial Measures

Certain non-GAAP financial measures are presented in this press release to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important operating performance indicators because they exclude items that are unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. To the extent the Company uses such non-GAAP financial measures in the future, they will be calculated using a consistent method from period to period. A reconciliation of each of the historical GAAP financial measures to the most directly comparable historical non-GAAP financial measures has been provided in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

The Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that may be made to the Company’s GAAP financial measures in calculating the non-GAAP financial measures.

In particular, the accounting treatment for Tandem Choice has a high degree of complexity. In September 2022 when the program was launched, the Company began deferring a portion of sales for each eligible t:slim X2 pump shipped in the United States. The total Tandem Choice deferral was $31.0 million as of June 30, 2024. When a customer elects to participate in Tandem Choice, the Company will recognize the existing deferral, incremental fees received and the associated costs of providing the new insulin pump at the time of fulfillment. The timing of recognition will be based on either a) an affirmative election to participate in Tandem Choice or b) expiration of the right to participate at program expiration.

Notably:

• Offering the program does not impact the economics associated with how or when the initial pump sale is reimbursed.
• Customer eligibility was automatic and no election was necessary to participate in Tandem Choice at the time of a t:slim X2 purchase. Customer eligibility ended in February 2024 with the commercial availability of the new hardware platform, Tandem Mobi.
• Qualifying customers were able to elect participation in Tandem Choice starting at the end of the second quarter of 2024.
• An affirmative election is required for the customer to participate in Tandem Choice, at which time any customer fees will be received and recognized as a sale. Any remaining deferrals will be recognized at program expiration.
• The expiration date of Tandem Choice is December 31, 2024.

Conference Call

The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To access the call by phone, please use this link (https://register.vevent.com/register/BIc1efe0f41c4149d2ae27551b0212f1cf) and you will be provided with dial-in details, including a personal pin.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results and the ability to achieve other operational and commercial goals. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s products; products marketed and sold or under development by competitors; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to successfully commercialize its products; the Company’s ability to develop and launch new products; risks associated with the regulatory approval process outside the United States for new products; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable, or may otherwise negatively impact the purchasing trends of customers; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
Table A
(in thousands)
	June 30,			December 31,
	2024			2023
Assets	(Unaudited)
Current assets:
Cash, cash equivalents and short-term investments	$	452,415		$	467,912
Accounts receivable, net		98,117			105,555
Inventories		161,661			157,937
Other current assets		21,195			16,585
Total current assets		733,388			747,989
Property and equipment, net		78,626			76,542
Operating lease right-of-use assets		88,243			87,791
Other long-term assets		37,246			40,336
Total assets	$	937,503		$	952,658
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable, accrued expenses and employee-related liabilities	$	103,872		$	105,742
Current portion of convertible senior notes, net		40,540			—
Operating lease liabilities		17,790			17,060
Deferred revenue		44,200			43,994
Other current liabilities		34,208			28,462
Total current liabilities		240,610			195,258
Convertible senior notes, net - long-term		307,392			285,035
Operating lease liabilities - long-term		111,392			113,572
Deferred revenue - long-term		11,736			13,331
Other long-term liabilities		32,498			31,830
Total liabilities		703,628			639,026
Total stockholders’ equity		233,875			313,632
Total liabilities and stockholders’ equity	$	937,503		$	952,658

TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Table B
(in thousands, except per share data)
(Unaudited)
	Three Months Ended June 30,								Six months ended June 30,
	2024				2023				2024				2023
Sales	$	221,910			$	195,917			$	413,584			$	365,300
Cost of sales		109,116				94,182				206,118				180,658
Gross profit		112,794				101,735				207,466				184,642
Operating expenses:
Selling, general and administrative		94,242				97,610				184,348				187,424
Research and development		49,326				42,933				95,570				85,093
Acquired in-process research and development expenses		—				—				—				78,750
Total operating expenses		143,568				140,543				279,918				351,267
Operating loss		(30,774	)			(38,808	)			(72,452	)			(166,625	)
Total other income (expense), net		1,031				4,179				3,180				8,410
Loss before income taxes		(29,743	)			(34,629	)			(69,272	)			(158,215	)
Income tax expense		1,071				1,146				4,257				1,433
Net loss	$	(30,814	)		$	(35,775	)		$	(73,529	)		$	(159,648	)
Net loss per share - basic and diluted	$	(0.47	)		$	(0.55	)		$	(1.13	)		$	(2.47	)
Weighted average shares used to compute basic and diluted net loss per share		64,994				64,830				65,160				64,690

TANDEM DIABETES CARE, INC.
SALES BY GEOGRAPHY
Table C(1)
	(Unaudited)
($'s in thousands)	Three Months Ended June 30,										Six months ended June 30,
	2024				2023				% Change		2024				2023				% Change
United States:
Pump	$	81,745			$	74,360			10%		$	143,465			$	140,816			2%
Supplies and other		74,812				70,450			6%			143,999				137,259			5%
Net revenue recognized (deferred) for Tandem Choice		154				(2,309	)		(107)%			(992	)			(4,332	)		(77)%
Total GAAP Sales in the United States	$	156,711			$	142,501			10%		$	286,472			$	273,743			5%
Adjustment for Tandem Choice		(154	)			2,309			(107)%			992				4,332			(77)%
Total Non-GAAP Sales in the United States	$	156,557			$	144,810			8%		$	287,464			$	278,075			3%
Outside the United States:
Pump	$	26,130			$	27,317			(4)%		$	51,697			$	45,563			13%
Supplies and other		39,069				26,099			50%			75,415				45,994			64%
Total Sales Outside the United States	$	65,199			$	53,416			22%		$	127,112			$	91,557			39%
Total GAAP Worldwide Sales	$	221,910			$	195,917			13%		$	413,584			$	365,300			13%
Adjustment for Tandem Choice		(154	)			2,309			(107)%			992				4,332			(77)%
Total Non-GAAP Worldwide Sales	$	221,756			$	198,226			12%		$	414,576			$	369,632			12%

(1)

A reconciliation of non-GAAP financial measures to their closest GAAP equivalent and additional information can be found in Table D and under the heading “Reconciliation of GAAP versus Non-GAAP Financial Results.”

TANDEM DIABETES CARE, INC.
Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited)
Table D
($'s in thousands)	Three Months Ended June 30,								Six months ended June 30,
	2024				2023				2024				2023
GAAP sales	$	221,910			$	195,917			$	413,584			$	365,300
Adjustment for Tandem Choice (1)		(154	)			2,309				992				4,332
Non-GAAP sales	$	221,756			$	198,226			$	414,576			$	369,632
GAAP gross profit	$	112,794			$	101,735			$	207,466			$	184,642
Adjustment for Tandem Choice(1)		(127	)			2,309				1,019				4,332
Non-GAAP gross profit	$	112,667			$	104,044			$	208,485			$	188,974
GAAP gross margin(2)		51	%			52	%			50	%			51	%
Non-GAAP gross margin(3)		51	%			52	%			50	%			51	%
GAAP operating loss	$	(30,774	)		$	(38,808	)		$	(72,452	)		$	(166,625	)
Acquired in-process research and development(4)		—				—				—				78,750
Non-recurring facility consolidation costs(4)		—				14,099				—				14,099
Severance costs - cash and noncash		—				—				—				2,680
Adjustment for Tandem Choice(1)		(127	)			2,309				1,019				4,332
Non-GAAP operating loss	$	(30,901	)		$	(22,400	)		$	(71,433	)		$	(66,764	)
GAAP operating margin(2)		(14	)%			(20	)%			(18	)%			(46	)%
Non-GAAP operating margin(3)		(14	)%			(11	)%			(17	)%			(18	)%
GAAP net loss	$	(30,814	)		$	(35,775	)		$	(73,529	)		$	(159,648	)
Income tax expense (benefit)		1,071				1,146				4,257				1,433
Interest income, interest expense and other, net		(1,031	)			(4,179	)			(3,180	)			(8,410	)
Depreciation and amortization		4,108				4,265				8,151				7,661
Stock-based compensation expense		24,897				23,400				46,936				44,205
Acquired in-process research and development(4)		—				—				—				78,750
Non-recurring facility consolidation costs(4)		—				14,099				—				14,099
Severance costs - cash and noncash		—				—				—				2,680
Adjustment for Tandem Choice(1)		(127	)			2,309				1,019				4,332
Adjusted EBITDA	$	(1,896	)		$	5,265			$	(16,346	)		$	(14,898	)
Adjusted EBITDA margin(3)		(1	)%			3	%			(4	)%			(4	)%
GAAP net loss	$	(30,814	)		$	(35,775	)		$	(73,529	)		$	(159,648	)
Acquired in-process research and development(4)		—				—				—				78,750
Non-recurring facility consolidation costs(4)		—				14,099				—				14,099
Severance costs - cash and noncash		—				—				—				2,680
Adjustment for Tandem Choice(1)		(127	)			2,309				1,019				4,332
Non-GAAP net loss	$	(30,941	)		$	(19,367	)		$	(72,510	)		$	(59,787	)

(1)		The accounting treatment for Tandem Choice has a high degree of complexity. Additional information can be found under the heading “Non-GAAP Financial Measures.”
(2)		GAAP margins including GAAP gross margin and GAAP operating margin are calculated using GAAP sales.
(3)		Non-GAAP margins including non-GAAP gross margin, non-GAAP operating margin, and adjusted EBITDA margin are calculated using non-GAAP sales.
(4)		Acquired in-process research and development charges representing the value of acquired in-process research and development assets with no alternative future use and acquisition related expenses recorded in connection with the acquisitions of AMF Medical SA in 2023.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240801786831/en/

Media Contact:

858-366-6900

media@tandemdiabetes.com

Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

FAQ

What were Tandem Diabetes Care's Q2 2024 GAAP sales?

Tandem Diabetes Care's Q2 2024 GAAP sales were $221.9 million, marking a 13% increase from Q2 2023.

How many insulin pumps did Tandem Diabetes Care ship in Q2 2024?

Tandem Diabetes Care shipped more than 20,000 insulin pumps in the US in Q2 2024, a 33% sequential increase.

What new products did Tandem Diabetes Care launch in Q2 2024?

Tandem Diabetes Care launched the Tandem Mobi integrated with Dexcom G7 CGM in the US and began the international rollout of Tandem Source.

What is the net loss reported by Tandem Diabetes Care for Q2 2024?

Tandem Diabetes Care reported a GAAP net loss of $30.8 million for Q2 2024.

Did Tandem Diabetes Care provide any guidance for full-year 2024?

Yes, Tandem Diabetes Care increased its full-year 2024 sales guidance due to strong demand for its latest technologies.